Literature DB >> 15244521

Population-based survival from cancers having a poor prognosis in Mumbai (Bombay), India.

Balkrishna Bhika Yeole1, A Venkata Ramana Kumar.   

Abstract

BACKGROUND: Oesophagus, stomach, pancreas and lung cancers contribute more than 35% of the total cancer incidence in Mumbai and survival rates for these cancers are very poor in most populations in the world. The authors here report and discuss the population-based survival from these cancers in Mumbai, India.
METHODS: Follow-up information on 5717 cancers patients having a low prognosis, registered in the Mumbai Population-Based Cancer Registry for the period 1987-1991, was obtained by a variety of methods, including matching with death certificates from the Mumbai vital statistics registration system, postal/telephone enquiries, home visits and scrutiny of medical records. The survival for each case was determined as the duration between the date of diagnosis and date of death, loss to follow-up or the closing date of the study at the end of 1996. Cumulative observed and relative survival rates were calculated by the Hakulinen Method. For comparison of results with other populations, age-standardized relative survival (ASRS) was calculated by directly standardizing age specific relative survival to the specific age distributions of the estimated global incidence of major cancers in 1985. The log rank test was used with univariate analysis to identify the potentially important prognostic variables. The variables showing statistical significance in univariate analysis were introduced stepwise into a Cox Regression model to identify the independent predictors of survival.
RESULTS: The 5-year relative survival rates were 11.8% for oesophagus, 10.1% for the stomach, 4.1% for the pancreas, and 7.0% for lung. Females had higher survival rates than males, except with lung cancer. Lower survival was observed for those younger than 35 years for all 4 sites. For each site, survival declined with advancing age. Single patients who remained unmarried had better survival, except with pancreatic cancer. For all sites Muslims had a better survival and Christians had a lower survival as compared to Hindus. Education did not show any pattern for any site. Survival decreased rapidly with advancing clinical extent of disease for all sites. Survival for localized cancer ranged from 12.5% to 31.3%, for regional spread 1.3% to 3.4% and with distant metastasis not a single site recorded more than 1%. On multivariate analysis, extent of disease emerged as an independent predictor of survival with all the sites. Also, age for oesophagus, stomach and lung, religion for oesophagus and stomach, and education for stomach and lung, emerged as independent predictors of survival.
CONCLUSION: All the sites included in the study demonstrated very low survival rates with significant variation. Comparison with other populations revealed lower survival rates than for Shanghai-China. In remaining populations, survival proportions did not show much variation for pancreas and lung cancers. For stomach cancer, European countries showed better survival rates. Early detection with treatment is clearly important to reduce the mortality from these cancers.

Entities:  

Mesh:

Year:  2004        PMID: 15244521

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  12 in total

1.  Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute.

Authors:  Yajie Zhao; Chengfeng Wang
Journal:  J Gastrointest Surg       Date:  2019-04-03       Impact factor: 3.452

2.  Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis.

Authors:  Kumar Anupam; Chatopadhyay Tusharkant; Siddhartha Datta Gupta; Ralhan Ranju
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

3.  Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  Indian J Surg Oncol       Date:  2011-02-17

4.  Treatment Access and Survival Amongst British Asians with Pancreatic Cancer.

Authors:  J Isherwood; D Bilku; M S Metcalfe; A R Dennison; G Garcea
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

5.  CA 19-9 and pancreatic cancer.

Authors:  Erxi Wu; Shuang Zhou; Kruttika Bhat; Qingyong Ma
Journal:  Clin Adv Hematol Oncol       Date:  2013-01

6.  Surgery for pancreatic carcinoma: state of the art.

Authors:  Shailesh V Shrikhande; Savio George Barreto
Journal:  Indian J Surg       Date:  2011-11-24       Impact factor: 0.656

7.  siRNA-mediated downregulation of TC21 sensitizes esophageal cancer cells to cisplatin.

Authors:  Raghibul Hasan; Shyam Singh Chauhan; Rinu Sharma; Ranju Ralhan
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

8.  Gastric cancer prevalence, according to survival data in iran (national study-2007).

Authors:  Aa Mehrabian; F Esna-Ashari; H Zham; M Hadizadeh; M Bohlooli; M Khayamzadeh; Me Akbari
Journal:  Iran J Public Health       Date:  2010-09-30       Impact factor: 1.429

9.  Prognostic factors for esophageal squamous cell carcinoma--a population-based study in Golestan Province, Iran, a high incidence area.

Authors:  Karim Aghcheli; Haji-Amin Marjani; Dariush Nasrollahzadeh; Farhad Islami; Ramin Shakeri; Masoud Sotoudeh; Behnoush Abedi-Ardekani; Mohammad-Reza Ghavamnasiri; Ezzatollah Razaei; Elias Khalilipour; Samira Mohtashami; Yasha Makhdoomi; Rabea Rajabzadeh; Shahin Merat; Rasoul Sotoudehmanesh; Shahryar Semnani; Reza Malekzadeh
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

10.  Application of artificial neural network in predicting the survival rate of gastric cancer patients.

Authors:  A Biglarian; E Hajizadeh; A Kazemnejad; Mr Zali
Journal:  Iran J Public Health       Date:  2011-06-30       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.